A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy

Inclusion Criteria: * Participant must have confirmation of Acute Myeloid Leukemia (AML) by World Health Organization (WHO) criteria, previously untreated and unfit for intensive chemotherapy * Participant must be \>= 60 years of age. * Participant must have a projected life expectancy of at least 12 weeks. * Participant must have adequate renal function as demonstrated by a creatinine \>= 30 mL/min;determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula * Participant must have adequate liver function as demonstrated by: 1. aspartate aminotransferase (AST) \<= 3.0 x ULN\* 2. alanine aminotransferase (ALT) \<= 3.0 x ULN\* 3. bilirubin \<= 1.5 x ULN\* \* Unless considered to be due to leukemic organ involvement i. Subjects who are \< 75 years of age may have a bilirubin of \<= 3.0 x ULN Exclusion Criteria: * Participant has history of myeloproliferative neoplasm (MPN) including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation * Participant has acute promyelocytic leukemia * Participant has known active central nervous system (CNS) involvement with AML * Participant is known to be positive for hepatitis B or C infection * Participant has received anticancer therapies including chemotherapy, radiotherapy or other investigational therapy, including targeted small molecule agents within 5 half-lives prior to first dose of study drug * Participant has received biologic agents (e.g. monoclonal antibodies) for anti-neoplastic intent within 30 days prior to first dose of study drug * Participant has received the following within 7 days prior to the first dose of the study drug: 1. Steroid therapy for anti-neoplastic intent; 2. Strong and Moderate CYP3A inhibitors (see Appendix A for examples) 3. Strong and Moderate CYP3A inducers (see Appendix A for examples) * Participant exhibits evidence of other clinically significant uncontrolled systemic infection requiring therapy * Participant has a serious cardiovascular, pulmonary or renal disability * Participant has a history of other malignancies within 2 years prior to study entry, with the exception of: 1. Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast; 2. Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; 3. Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; requires discussion with TA MD.